Can you provide a SOAP note for a 40-year-old female seeking pharmacologic weight‑loss therapy who also has chronic eczema rash and bilateral plantar fasciitis?

SOAP Note for 40-Year-Old Female with Weight Loss Request, Eczema, and Bilateral Plantar Fasciitis

SUBJECTIVE

Chief Complaint: Seeking weight loss medication; also reports chronic eczema rash and bilateral heel pain.

History of Present Illness:

• Weight/Obesity: Document current weight, height, BMI. Inquire about previous weight loss attempts (diet, exercise programs, duration, results). Ask about weight-related complications: hypertension, dyslipidemia, diabetes, sleep apnea, joint pain. Assess readiness for lifestyle modification and medication adherence.

• Eczema: Characterize location, duration, severity, pruritus intensity, impact on quality of life and sleep. Document previous treatments tried (topical corticosteroids, topical calcineurin inhibitors, moisturizers) and their effectiveness. Ask about flare triggers and family history of atopic conditions.

• Plantar Fasciitis: Elicit classic symptom of sharp heel pain with first steps in morning or after rest. Document duration (acute vs chronic >6 months), bilateral involvement, functional limitations, previous treatments (stretching, NSAIDs, orthotics, physical therapy, injections), and occupational factors.

Medications: Current medications, particularly MAO inhibitors (contraindication for certain weight loss drugs), antihypertensives, antidepressants.

Past Medical History: Depression, anxiety, suicidal ideation, seizure disorder, uncontrolled hypertension, cardiovascular disease, liver disease, malabsorption disorders, history of bariatric surgery.

Social History: Smoking status (relevant for naltrexone-bupropion), alcohol use, occupation (standing/walking requirements).

OBJECTIVE

Vital Signs: Weight, height, BMI, blood pressure, heart rate (essential for weight loss medication monitoring).

Physical Examination:

• Skin: Document eczema distribution, severity (erythema, lichenification, excoriation), body surface area involved. Assess for secondary infection.
• Feet: Point tenderness at medial calcaneal tubercle bilaterally (plantar fascia origin). Assess gastrocnemius tightness with dorsiflexion. Evaluate gait, foot alignment, and footwear.
• General: Assess for signs of weight-related complications.

Laboratory/Imaging: Consider baseline labs if initiating weight loss medication (lipid panel, HbA1c, liver function tests). Imaging for plantar fasciitis only if atypical presentation or failed conservative management 1.

ASSESSMENT

1. Obesity (BMI ≥30 kg/m² or BMI ≥27 kg/m² with comorbidities) - candidate for pharmacotherapy
2. Atopic dermatitis (eczema) - moderate to severe based on extent and QOL impact
3. Bilateral plantar fasciitis - chronic (if >6 months) or acute

PLAN

Weight Loss Management

For this 40-year-old female seeking weight loss medication, I recommend initiating GLP-1 receptor agonist therapy (semaglutide or liraglutide 3.0 mg) as first-line pharmacotherapy if BMI criteria are met, combined with structured lifestyle interventions including a 500-800 kcal/day deficit diet and 30 minutes of physical activity most days. 2

Medication Selection Algorithm:

• First-line: GLP-1 agonists (semaglutide 2.4 mg weekly or liraglutide 3.0 mg daily) - highest efficacy for weight loss
• Alternative if GLP-1 contraindicated/not tolerated: Phentermine monotherapy (off-label beyond 12 weeks but commonly used) - conditional recommendation with 3.63% TBWL vs placebo 2
• Avoid: Orlistat - conditional recommendation AGAINST due to modest efficacy (only included for completeness as guideline discusses it) and high GI adverse effects 2
• Consider: Naltrexone-bupropion ER if patient is also a smoker, but avoid if uncontrolled hypertension or on MAO inhibitors; monitor for neuropsychiatric effects 2

Monitoring:

• Vital signs at each visit (especially with naltrexone-bupropion or phentermine)
• Assess 5% and 10% total body weight loss thresholds
• If inadequate response after 12-16 weeks, consider switching agents
• Multivitamin with fat-soluble vitamins if using orlistat (taken 2 hours apart) 2

Contraindications to screen for:

• Uncontrolled hypertension (for phentermine, naltrexone-bupropion)
• MAO inhibitor use within 14 days (for naltrexone-bupropion)
• History of suicidal ideation, especially if age <24 years (for naltrexone-bupropion)
• Chronic malabsorption, IBD, prior bariatric surgery (for orlistat)

Eczema Management

Optimize topical therapy first with high-potency topical corticosteroids for flares and topical calcineurin inhibitors for maintenance, combined with aggressive emollient use and trigger avoidance. 3

If inadequate control despite optimized topical therapy:

• Consider systemic therapy: Dupilumab (IL-4/IL-13 inhibitor) or tralokinumab (IL-13 inhibitor) are FDA-approved biologics with excellent safety profiles 3
• Tralokinumab specifically has demonstrated efficacy in dyshidrotic palmoplantar eczema in a 40-year-old female 4
• Rule out alternative diagnoses (contact dermatitis, cutaneous lymphoma) if atypical

Patient education: Daily emollients, identify and avoid triggers, proper TCS application technique.

Bilateral Plantar Fasciitis Management

Initiate core conservative treatment with plantar fascia and gastrocnemius stretching exercises, taping techniques, and individualized education about activity modification and proper footwear. 5

Stepped-Care Algorithm:

1. Initial treatment (0-3 months):

   • Plantar fascia stretching (strong evidence: SMD 1.21 for first-step pain) 5
   • Gastrocnemius stretching (addresses underlying tightness) 1
   • Taping (SMD 0.47 for short-term first-step pain) 5
   • Activity modification, NSAIDs, heel cushioning
   • In-shoe orthosis that lifts and cushions heel 1
   • Expected resolution in 90% of patients within 3-6 months 1, 6

2. If inadequate response at 3-6 months:

   • Custom foot orthoses (SMD 0.41 short-term, 0.55 medium-term for general pain) 5
   • Focused or radial shockwave therapy (strong evidence: OR 1.89 short-term, SMD 1.67 long-term for focused shockwave) 5

3. If refractory after 6-12 months:

   • Consider platelet-rich plasma injections, therapeutic ultrasound 1
   • Avoid corticosteroid injections - temporary relief but increased risk of plantar fascia rupture and fat pad atrophy 1
   • Botulinum toxin injections (relaxes calf muscles) 1
   • Surgical options: gastrocnemius recession or partial plantar fasciotomy 1, 6

Patient education: Demonstrate proper stretching technique, emphasize consistency (daily stretching), appropriate footwear selection, avoid barefoot walking.

Follow-up

• 2-4 weeks: Assess weight loss medication tolerance, vital signs, eczema response to topicals, plantar fasciitis pain improvement with stretching/taping
• 3 months: Evaluate weight loss efficacy (target ≥5% TBWL), consider systemic therapy for eczema if inadequate topical response, reassess plantar fasciitis
• 6 months: Consider advanced interventions for plantar fasciitis if persistent symptoms despite conservative management

Common Pitfalls to Avoid:

• Starting weight loss medication without establishing lifestyle modification commitment
• Using corticosteroid injections for plantar fasciitis (rupture risk)
• Neglecting to supplement fat-soluble vitamins if using orlistat
• Failing to monitor blood pressure with sympathomimetic weight loss agents
• Undertreating moderate-to-severe eczema with topicals alone when systemic therapy indicated